Loading organizations...
Artios Pharma is a clinical-stage biopharmaceutical company developing precision cancer treatments targeting the DNA Damage Response pathway, headquartered in Cambridge, United Kingdom, with operations in New York. The organization focuses on creating first-in-class therapies, including the clinical-stage ATR inhibitor alnodesertib, designed to exploit the vulnerabilities of hard-to-treat solid tumors. To support its clinical trials and proprietary pipeline, the enterprise has secured over $320 million in total equity funding, highlighted by a $153 million Series C financing round. The company maintains strategic research collaborations with major pharmaceutical corporations Novartis and Merck KGaA, which feature potential milestone payments exceeding $7 billion combined. Institutional backing comes from a syndicate of notable venture capital investors, including Pfizer Ventures, SV Health Investors, and RA Capital. Artios Pharma was established in 2016 by founding chief executive officer Dr. Niall Martin.
Artios Pharma has raised $386.0M across 4 funding rounds.
Artios Pharma has raised $386.0M in total across 4 funding rounds.
Artios Pharma has raised $386.0M in total across 4 funding rounds.
Artios Pharma's investors include Jake Simson, Nikola Trbovic, Andera Partners, EQT Life Sciences, Hakan Goker, M Ventures (Merck), Novartis Venture Fund, Pfizer Venture Investments, Avidity Partners, Invus, Janus Henderson Investors, LSP.
Artios Pharma is a clinical-stage biotechnology company developing novel cancer therapies that target DNA Damage Response (DDR) pathways to treat hard-to-treat solid tumors.[1][3] It builds a pipeline of first-in-class and best-in-class drugs, including the ATR inhibitor alnodesertib (ART0380) in Phase 1/2 trials for advanced solid neoplasms, the Polθ inhibitor ART6043 in Phase 1/2 for BRCA-mutant breast cancer and other cancers, and preclinical programs like DDR inhibitor-Antibody Drug Conjugates (DDRi-ADCs).[1][4][6] Artios serves oncology patients by inducing DNA damage selectively in cancer cells while sparing healthy tissue, addressing replication stress and resistance mechanisms in tumors like pancreatic, colorectal, and breast cancers.[1][3][6] The company has raised $270.2M total, including an oversubscribed $115M Series D in 2025 to advance clinical programs, showing strong growth momentum with promising early trial data and partnerships with Merck KGaA and Novartis.[3][6]
Artios Pharma was founded in May 2016 in Cambridge, UK, by industry-leading experts who pioneered the field of DDR therapeutics, including the inventors of the blockbuster PARP inhibitor Lynparza (olaparib), now marketed by AstraZeneca.[1][3][4] The founders leveraged decades of DDR insights from collaborations with Cancer Research UK and Cancer Research Technology (CRT) to establish a bespoke DDR drug discovery platform at the Babraham Institute.[4] Early traction came from building a robust pipeline and securing investments from backers like SV Life Sciences and Merck Ventures, enabling rapid advancement into clinical stages.[4][6] Pivotal moments include the 2020 Merck KGaA license for nuclease inhibitors and the 2021 Novartis collaboration for radioligand therapy sensitizers, validating their technology.[2][5]
Artios stands out in the DDR field through:
Artios rides the surging wave of precision oncology, where DDR inhibitors address cancer cells' reliance on DNA repair to evade chemotherapy, radiation, and immunotherapies amid rising replication stress from tumor evolution.[1][3] Timing is ideal as radioligand therapies (e.g., Novartis' 177Lu compounds) gain approvals for neuroendocrine tumors and metastases, creating demand for DDR sensitizers to boost efficacy and combat resistance—Artios' collaborations directly capitalize on this.[5] Market forces like expanding clinical validations (e.g., alnodesertib shrinking tumors in trials) and investor enthusiasm (€261M+ raised) favor DDR leaders, influencing the ecosystem by licensing IP to pharma giants and advancing next-gen modalities like ADCs.[3][6] This positions Artios to shape DDR as a cornerstone of multi-modal cancer treatment.
Artios is primed for registration paths with alnodesertib and ART6043, targeting pancreatic, colorectal, and breast cancers via planned Phase 2 trials, while its DDRi-ADC could enter clinic in 2026.[6] Trends like AI-driven screening, radioligand expansion, and combo therapies will accelerate its pipeline, potentially yielding approvals in underserved indications.[5][6] Its influence may evolve from innovator to platform licensor, mirroring Lynparza's blockbuster trajectory, solidifying Artios as the foremost DDR biotech amid oncology's shift to selective DNA-targeting therapies—echoing its founding mission to transform hard-to-treat cancer outcomes.[1]
Artios Pharma has raised $386.0M across 4 funding rounds. Most recently, it raised $120.0M Series D in November 2025.
